Stephanie Campos
Payments from drug & device makers
Across 136 payments — averaging $26.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$531
- AstraZeneca$462
- Ardelyx, Inc.$400
- Mallinckrodt Hospital Products Inc.$363
- ANI Pharmaceuticals, Inc.$326
- Novartis$252
- plus $1K from 11 others
What the payments were for
- Food & beverage$3,599100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 10 | $531 |
| AstraZeneca | 15 | $462 |
| Ardelyx, Inc. | 16 | $400 |
| Mallinckrodt Hospital Products Inc. | 17 | $363 |
| ANI Pharmaceuticals, Inc. | 12 | $326 |
| Novartis | 9 | $252 |
| OPKO Pharmaceuticals, LLC | 11 | $240 |
| Bayer | 8 | $202 |
| Kyowa Kirin, Inc. | 8 | $191 |
| Calliditas Therapeutics US Inc. | 13 | $184 |
| Otsuka America Pharmaceutical, Inc. | 6 | $140 |
| Scpharmaceuticals Inc. | 3 | $126 |
| Amgen | 2 | $48 |
| Aurinia Pharma U.S., Inc. | 2 | $44 |
| Lilly USA, LLC | 2 | $42 |
| Merck | 1 | $25 |
| Akebia Therapeutics Inc | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,599 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 206 | $155,994 |
| FarxigaDapagliflozin Propanediol | 164 | $133,749 |
| KerendiaFinerenone | 45 | $43,739 |
| OzempicSemaglutide | 27 | $25,386 |
| LokelmaSodium Zirconium Cyclosilicate | 30 | $18,431 |
| EliquisApixaban | 19 | $11,271 |
| Calcitriol | 119 | $2,137 |
| Potassium Citrate ErPotassium Citrate | 20 | $2,111 |
| Nifedipine ErNifedipine | 55 | $1,139 |
| Torsemide | 29 | $856 |
| Tamsulosin Hcl | 117 | $839 |
| Losartan Potassium | 76 | $721 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 98 | $590 |
| Cinacalcet Hcl | 12 | $563 |
| Mirtazapine | 15 | $504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $531 | $155,994206 claims |
| AstraZenecaFarxiga, Lokelma | $462 | $152,179194 claims |
| BayerKerendia | $202 | $43,73945 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $326 | $21518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Miami
- Stephanie MompointMiami$4.5M
- Itsel Cardenas RamonMiami$1M
- Patrick SzarazMiami$327K
- Yamila MelendezMiami$212K
- Suzan RosenMiami$129K
- Felipe NovoaMiami$110K
- Pamela DudkiewiczMiami$89K
- Stacy FeemsterMiami$51K
- John HuffakerVenice$8M
- Miguel TrujilloMiami Gardens$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.